Gregory Braden, MD

Acute Myocardial Infarction: Early Strategies to Optimize Results

06/19/2008

Roxana Mehran , MD;

Fayaz Shawl , MD;

Ted A. Bass , MD;

Gregory Braden , MD;

Paul A. Overlie , MD, FACC, FACP;

Norberto Schechtmann , MD;

Patrick L. Whitlow , MD;

William W. O'Neill , MD;

Raoul Bonan , MD;

Greg Braden: Let’s discuss the issue of MI patients who live in communities where there is quick access to catheterization laboratories, versus those in remote communities who don’t have easy access to cath labs. We live in a modestly rural...

Greg Braden: Let’s discuss the...

06/19/2008

Cath Lab Digest

Feature

Acute Myocardial Infarction: Early Strategies to Optimize Results

06/19/2008

Gregory Braden , MD;

Paul A. Overlie , MD, FACC, FACP;

Fayaz Shawl , MD;

Roxana Mehran , MD;

Norberto Schechtmann , MD;

Ted A. Bass , MD;

Patrick L. Whitlow , MD;

William W. O'Neill , MD;

Raoul Bonan , MD;

Greg Braden: Let’s discuss the...

06/19/2008

Cath Lab Digest

Feature

Clinical Efficacy of Vascular Brachytherapy in the Cath Lab

08/01/2008

Gregory Braden , MD;

Greg Braden: Thank you, Bill. I appreciate the opportunity to be here and share this webcast with you. We will briefly discuss the clinical efficacy of vascular brachytherapy and review our own local experience, much like what Dean has shown...

Greg Braden: Thank you, Bill. I...

08/01/2008

Journal of Invasive Cardiology

Feature

Questions and Answers (May 14, 2002)

08/01/2008

Dean J. Kereiakes , MD, FACC, FSCAI;

William W. O'Neill , MD;

Gregory Braden , MD;

Stephen R. Ramee , MD;

May 14, 2002 William O’Neill: There is a question for Dean Kereiakes. How will decreasing or eliminating restenosis impact surgical volume — obviously a major concern for surgeons and hospitals because coronary bypass surgery is a very...

May 14, 2002 William O’Neill:...

08/01/2008

Journal of Invasive Cardiology

Feature

Questions and Answers (May 15, 2002)

08/01/2008

Dean J. Kereiakes , MD, FACC, FSCAI;

William W. O'Neill , MD;

Gregory Braden , MD;

Stephen R. Ramee , MD;

May 15, 2002 Scott McMahon: Our first question is as follows: Do drug-eluting stents eliminate the need for IIb/IIIa platelet inhibitors and their associated costs which are reimbursed in DRG 516? William O’Neill: Dean, could you comment on...

May 15, 2002 Scott McMahon: Our...

08/01/2008

Journal of Invasive Cardiology

Feature

Questions and Answers (May 16, 2002)

08/01/2008

Dean J. Kereiakes , MD, FACC, FSCAI;

William W. O'Neill , MD;

Gregory Braden , MD;

Stephen R. Ramee , MD;

May 16, 2002 Scott McMahon: The first question this evening is as follows: What is your estimate of the aggregate increase or decrease in PCI procedures at one, two and five years following the introduction of drug-eluting stents? William...

May 16, 2002 Scott McMahon: The...

08/01/2008

Journal of Invasive Cardiology

IAGS (International Andreas Gruentzig Society) Proceedings

Drug-Eluting Stents: Current Limitations

08/01/2008

Jamey Jacobs ;

Tim A. Fischell , MD, FACC, FSCAI;

Jorge A. Belardi , MD, PhD;

Christopher U. Cates , MD;

Alfredo E. Rodriguez , MD, PhD;

Gregory Braden , MD;

Mike Cowley , MD;

David Sperling , MD;

Robert Fischell , MD;

Mike Cowley: Let’s begin with discussing case selection. Which patients should receive drug-eluting stents (DES)? Should they only receive one stent? Should we reserve DES for a select patient population? What should the approach be for...

Mike Cowley: Let’s begin with...

08/01/2008

Journal of Invasive Cardiology

Teaching Collection

International Andreas Gruentzig Society 8th Biennial Meeting: Acute Myocardial Infarction: Early Strategies to Optimize Results

08/01/2008

Patrick L. Whitlow , MD;

William W. O'Neill , MD;

Fayaz Shawl , MD;

Raoul Bonan , MD;

Gregory Braden , MD;

Paul A. Overlie , MD, FACC, FACP;